Andre Uddin Archives - BioTuesdays

Markets

RC ups PT; RJ reiterates ‘strong buy’, for Eupraxia on Phase 2b osteoarthritis data

Research Capital raised its price target for Eupraxia Pharmaceuticals (TSX:EPRX) to $25 (Canadian) from $10.30 and maintained a “speculative buy” rating after the company reported positive results from its Phase 2b...

June 26, 2023

Markets

Research Capital ups Profound Medical to speculative buy; PT to $17.25

Research Capital upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “speculative buy” from “hold” and raised its price target to $17.25 from $10.90, after the AMA approved three new Category 1 CPT codes for prostate...

June 5, 2023

Markets

Research Capital likes Theralase data update; sees FDA breakthrough filing soon

Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given the “strong data that has...

May 31, 2023

Markets

Research Capital remains bullish of Theralase’s Ruvidar in NMIBC after new data

April 27, 2023

Markets

Research Capital sees Theralase’s Ruvidar NMIBC as potentially better than Keytruda

Research Capital likes the potential chances of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar photodynamic therapy being better than Merck’s Keytruda for treating Bacillus Calmette-Guérin (BCG)-unresponsive...

February 23, 2023

Markets

Research Capital starts Eupraxia at speculative buy; PT $10.30 (Canadian)

Research Capital launched coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with a “speculative buy” rating and price target of $10.30 (Canadian). The stock closed at $3.69 on Jan. 6. Eupraxia’s lead product, EP...

January 9, 2023

Markets

Research Capital: Theralase bladder cancer data trending ahead of Keytruda

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) released updated interim data from its Phase 2 pivotal trial with its key value driver, TLD-1433, activated by its proprietary TLC-3200 medical laser system, that Research...

November 30, 2022

Markets

Research Capital ups Valeo Pharma PT on new drug licensing

Research Capital raised its price target for Valeo Pharma (CSE:VPH) to $1 (Canadian) from 70 cents and maintained a “speculative buy” rating after the company closed a $40-million (U.S.) non-dilutive financing from...

August 2, 2022

Markets

Research Capital downgrades Bellus Health on valuation, financing

Research Capital downgraded Bellus Health (NASDAQ:BLU) to “hold” from “speculative buy” and removed its previous $14.50 price target so “we can properly account for the new dilution” from a $153-million offering of new...

July 14, 2022

Markets

Mackie Research cuts Cipher Pharma to hold; PT to $1 (Canadian) from $1.50

Mackie Research Capital downgraded Cipher Pharmaceuticals (TSX:CPH) to “hold” from “buy” and reduced its price target to $1 (Canadian) from $1.50, citing marketing uncertainty, partially due to a recent unfavorable...

January 25, 2021

Tag - Andre Uddin

RC ups PT; RJ reiterates ‘strong buy’, for Eupraxia on Phase 2b osteoarthritis data

Research Capital ups Profound Medical to speculative buy; PT to $17.25

Research Capital likes Theralase data update; sees FDA breakthrough filing soon

Research Capital remains bullish of Theralase’s Ruvidar in NMIBC after new data

Research Capital sees Theralase’s Ruvidar NMIBC as potentially better than Keytruda

Research Capital starts Eupraxia at speculative buy; PT $10.30 (Canadian)

Research Capital: Theralase bladder cancer data trending ahead of Keytruda

Research Capital ups Valeo Pharma PT on new drug licensing

Research Capital downgrades Bellus Health on valuation, financing

Mackie Research cuts Cipher Pharma to hold; PT to $1 (Canadian) from $1.50

General

More